Redwire (RDW) said Tuesday that it was awarded a NASA contract to launch four additional pharmaceutical drug investigations at the International Space Station using the company's pharmaceutical in-space laboratory.

Financial terms were not disclosed.

The NASA-funded investigations aim to manufacture protein-based and other molecular seed crystals which could provide insights and data for low-gravity pharmaceutical manufacturing operations aboard the space station and other commercial space stations in low Earth orbit, the company said.

The company said previous investigations suggest that growing crystals in space could yield a more uniform product with fewer imperfections, the company said.